Health Care & Hospitals

CREATV BIO PRESENTS CANCER SCREENING AND CANCER DIAGNOSTICS DATA AT 1ST INTERNATIONAL CONFERENCE ON POLYPLOID GIANT CANCER CELLS

by

HOUSTON, April 30, 2024 /PRNewswire/ — Creatv Bio, A Division of Creatv MicroTech, Inc. (Creatv), (https://creatvbio.com/) and collaborators were invited to present clinical data from Creatv’s blood test for cancer screening and diagnostics at the 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications – held February 16 and 17 at The University … Read more

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

by

SAN DIEGO, April 30, 2024 /PRNewswire/ — Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $11.8M grant for further development of DB107, Denovo’s DGM7™ biomarker–guided late–stage gene therapy, for high–grade glioma (HGG) including glioblastoma … Read more

Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design

by

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency OXFORD, England, April 30, 2024 /PRNewswire/ — Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease … Read more

OMRON dona unas 3.200 unidades de monitores de presión arterial en el Día Mundial de la Hipertensión

by

– OMRON dona unas 3.200 unidades de monitores de presión arterial a la campaña mundial de detección de presión arterial en el Día Mundial de la Hipertensión KIOTO, Japón, 30 de abril de 2024 /PRNewswire/ — OMRON Healthcare Co., Ltd., con sede en Muko, prefectura de Kioto, Japón, anuncia ser el patrocinador oficial del Mes … Read more

Immunovia publishes the annual report for 2023

by

LUND, Sweden, April 29, 2024 /PRNewswire/ — Immunovia AB (publ) today announced that the Annual Report for 2023 has been published.  The annual report can be downloaded in pdf format and is available on Immunovia’s website: https://investor.immunovia.com/financial-reports-presentations/. For more information, please contact:Karin Almqvist LiwendahlChief Financial Officer[email protected]+46 709 11 56 08 Immunovia in brief  Immunovia AB … Read more

Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™

by

JERSEY CITY, N.J., April 28, 2024 /PRNewswire/ — Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the … Read more

OBiO Technology will showcase at American Society of Gene & Cell Therapy

by

-Visit OBiO Tech booth #1644 at  American Society of Gene & Cell Therapy in Maryland, USA SHANGHAI, April 28, 2024 /PRNewswire/ — OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9 posters will … Read more

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

by

STOCKHOLM, April 20, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate … Read more

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

by

STOCKHOLM, April 20, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate … Read more

Building Brighter Futures Dinner” Raises Funds for Early Childhood Education

by

LOS ANGELES, April 19, 2024 /PRNewswire-HISPANIC PR WIRE/ — Pathways LA, a leading Resource and Referral Childcare Agency and advocate for early childhood education and family support services, hosted its yearly fundraising event, “Seeds of Hope: Building Brighter Futures Dinner,” on Saturday, April 13. The event attracted a diverse array of attendees, including elected officials, … Read more